摘要
目的:分析厄贝沙坦联合胺碘酮治疗非瓣膜性阵发性心房颤动的临床效果。方法:选择2011年6月-2013年6月本院76例非瓣膜性阵发性心房颤动患者,随机分为治疗组、对照组,每组38例。两组均给予常规对症治疗,治疗组采用厄贝沙坦联合胺碘酮治疗,对照组口服胺碘酮治疗。结果:治疗组治疗9个月后心房颤动发作次数、发作持续时间明显减少,对照组左房内径明显大于治疗组,差异有统计学意义(P<0.05)。治疗组用药后的窦性心律维持率(94.7%)明显优于对照组(P<0.05)。两组均未出现用药原因的不良反应。结论:厄贝沙坦联合胺碘酮治疗非瓣膜性阵发性房颤有维持窦性心律和抑制左心房扩大的作用,疗效显著。
Objective：To analyze the clinical efficacy of irbesartan combined with ammonia amiodarone in treatment of non-valvular paroxysmal atrial fibrillation.Method：76 patients with non-valvular paroxysmal atrial fibrillation admitted into our hospital from June 2011 to June 2013 were randomly divided into treatment group and control group,with 38 cases in each group on average.Patients in the treatment group were treated with irbesartan jointly with ammonia amiodarone,and the control group were treated with ammonia amiodarone.Result：The episodes and duration of atrial fibrillation of the patients in the treatment group after 9 months of treatment were significantly reduced,and the left atrial diameter of the control group was significantly higher than that of the treatment group,and the difference was statistically significant.Sinusrhythm maintenance rate（94.7%） was maintained after treatment, which was significantly better than that of the control group.All patients showed no adverse reactions due to drug administration.Conclusion：Treatment of non-valvular atrial fibrillation using irbesartan combined ammonia amiodarone can maintain sinus rhythm and suppress the enlargement left atrium,with significant efficacy.
出处
《中国医学创新》
CAS
2015年第14期57-59,共3页
Medical Innovation of China
关键词
厄贝沙坦
胺碘酮
阵发性心房颤动
Irbesartan
Ammonia amiodarone
Paroxysmal atrial fibrillation
